While we expect this pivot to continue to be disruptive in the short-term, we believe it will lead to long-term growth and refinement of a strategy that we could utilise out of the gate in the US market. With the new strategic direction and near-term disruption, management expects preliminary, unaudited revenue for the second quarter of 2025 to be approximately $3 million and an operating loss of approximately $7 million as compared to an operating loss of $9.3 million in the second quarter of 2024
Thus, even if hailed a miracle drug, it does not necessarily mean that patent protection is guaranteed
By contrast, a recent clinical trial by Eli Lilly tracked nearly 400 subjects who switched from shots to Foundayo, and found that on average, they maintained most of their weight loss after 52 weeks
El pre-entreno con estimulantes contiene cafena u otros activadores para dar un chute de energa y concentracin, ideal para entrenar por la maana o a medioda
Lancet Gastroenterol Hepatol 2017
AAD 2015
